Your session is about to expire
← Back to Search
ABP 938 for Age-Related Macular Degeneration
Study Summary
This trial will compare the effectiveness of two drugs in treating age-related macular degeneration.
- Age-Related Macular Degeneration (AMD)
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 576 Patients • NCT04270747Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
To what purpose is ABP 938 typically employed?
"ABP 938 is a medication commonly prescribed to patients with wet age-related macular degeneration (wamd). This drug can also be used to mitigate macular edema, diabetic macular edema (dme), and other forms of macular degeneration."
What is the ABP 938 drug's official classification?
"ABP 938 has been given a safety rating of 3. This is due to it being a Phase 3 trial, where there is evidence of its efficacy as well as multiple rounds of data affirming its safety."
Could you please describe other similar medical studies to ABP 938?
"M D Anderson Cancer Center conducted the first study on ABP 938 in 2014. As of now, there have been a total of 231 completed trials. At the moment, there are 49 active studies, a majority of which are taking place in San Antonio and New york."
Are there different test sites for this clinical trial in the United States?
"So far, 53 different locations have been approved to operate for this study. These include Retina Associates of South Texas, P.A. in San Antonio, Ophthalmic Consultants of the Capital Region - Ophthalmology in Troy, and Colorado Retina Associates - Porter Hospital in Lakewood."
If a patient wanted to enroll in this clinical trial, could they?
"This clinical trial is not recruiting at the moment, but was last edited on 11/1/2022. There are 169 other trials for glycogen storage disease type ii and 49 for ABP 938 that are actively recruiting patients if you are interested."
How many people are you looking for to enroll in this trial?
"As of now, this clinical study is not admitting any new patients. The trial was first posted on June 22nd, 2020 and was last updated on November 1st, 2022. However, there are 169 other trials for glycogen storage disease type ii and 49 trials for ABP 938 that are currently looking for participants."
Share this study with friends
Copy Link
Messenger